Purpose: BMS-936558 is a monoclonal antibody that blocks the PD-1 co-inhibitory receptor expressed by activated T cells. This study describes its activity and safety in pts with previously treated advanced MEL. Methods: BMS-936558 was administered IV q2wk to pts with various tumors at 0.1 − 10 mg/kg during dose-escalation and/or cohort expansion. Pts received up to 12 cycles (4 doses/cycle) of treatment or until unacceptable toxicity, confirmed progressive disease, or complete response. Clinical activity was assessed by RECIST v1.0. Results: As of Feb 24, 2012, 104 MEL pts had received BMS-936558 at 0.1 (n = 17), 0.3 (n = 19), 1 (n = 31), 3 (n = 17), or 10 mg/kg (n = 20). ECOG performance status was 0/1/2 in 63/38/3 pts, respectively. Most pts (67/104) had received prior immunotherapy (IT); prior anti-CTLA-4, -PD-1, or -PD-L1 was not permitted. The number of prior therapies was 1 (39%), 2 (35%), or ≥3 (26%). Median therapy duration was 20 wks (range 2.0 − 121.7 wks). The incidence of grade 3 − 4 related AEs was 20% and included gastrointestinal (4%), endocrine (2%), and hepatobiliary disorders (1%). There were no drug-related deaths in MEL pts. Clinical activity (responses or prolonged stable disease) was observed at all doses (Table) . Of the 26/ 94 (28%) evaluable responders, 19 (73%) are ongoing ranging from 1.9+ to 24.9+ months. For the 23 responders followed ≥6 months from first dose on study, 16 (70%) are progression free. ORs occurred in pts with visceral or bone metastases. Six pts (6%; 95% CI 2 − 13%) had prolonged SD (≥24 wk); 3 pts had a persistent decrease in target lesion tumor burden in the presence of new lesions and were not categorized as responders. Conclusions: BMS-936558 had durable clinical benefit in pts with advanced MEL, including those who had received prior IT. Additional long-term follow-up data will be reported. Immunotherapeutics Bu, GlaxoSmithKline Biologicals, Rixensart, BELGIUM Introduction: Patients ( pts) with metastatic melanoma have a poor prognosis. The PRAME tumor antigen, expressed at high frequency in different cancers and at lower levels in a limited number of normal cells, offers an attractive target for active immunization. This open-label, dose-escalation phase I/II study aimed at determining the optimal dose of PRAME immunotherapeutic (PRAME recombinant protein (recPRAME) with AS15 immunostimulant) by evaluating its safety and immunogenicity in pts with advanced melanoma. Methods: Pts with stage IV PRAME-positive melanoma were enrolled to 3 consecutive cohorts to receive up to 24 injections of recPRAME (20 µg, 100 µg, and 500 µg) with AS15 (fixed dose) over approximately 4 years. Adverse events (AEs), including pre-defined dose-limiting toxicity (DLT), were recorded throughout the study. The anti-PRAME humoral and cellular responses were evaluated post-dose 4 by ELISA and flow cytometry (PRAME-specific T-cells producing both IFNγ and TNFα), respectively. Results: 66 pts were treated in the study (20 pts received 20 µg recPRAME, 24 pts received 100 µg recPRAME and 22 pts received 500 µg recPRAME). AEs considered by the investigator to be causally related were mostly grade 1/2, 2 pts reported grade 3 AEs, and 1 serious AE causally related to PRAME administration was reported. 2 DLTs were recorded in 2 pts (cohorts 2 and 3; post-dose 6 and 8) but no maximum tolerated dose was reached. Humoral and cellular immunological results are shown in table 1. No cellular response for CD8+ T-cells was detected. Conclusions: PRAME cancer immunotherapeutic was well-tolerated and induced similar humoral and cellular responses in all 3 cohorts. Based on these results, a phase II was initiated to further evaluate the clinical activity, safety and immunogenicity of the PRAME immunotherapeutic containing 500 µg recPRAME.
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Immunogenicity post-dose 4 (ATP population).
Cohort (recPRAME dose) 1 (20 µg) 2 (100 µg) 3 (500 µg) Humoral responders, n/N* 13/13 13/13 17/17 CD4+ T-cell responders, n/N* (%) 7/9 (78%) 7/11 (64%) 11/15 (73%) CD8+ T-cell responders, n/N* (%) 0/8 (0%) 0/9 (0%) 0/8 (0%) number of patients enrolled into each group; * number of patients with pre and post-vaccination results; n, number of responders; ATP, according-to-protocol Klinik für Dermatologie, Venerologie und Allergologie, Universitätsklinikum Schleswig-Holstein, Kiel, GERMANY Background: Vismodegib (Erivedge™, GDC-0449) is a first-in-class small-molecule inhibitor of the Hedgehog signaling pathway, which is implicated in the pathogenesis of BCC. ERIVANCE BCC is the pivotal trial of vismodegib for treatment of locally advanced (laBCC) and metastatic BCC (mBCC) patients ( pts) for whom there are no other effective therapies. The study met its primary endpoint of overall response rate by independent review (Dirix, ESMO 2011 LBA#1) . On behalf of the ERIVANCE BCC investigators, we present the previously unreported updated investigator-assessed (I-A) efficacy and safety endpoints as of Nov 28, 2011 (additional 12 months of follow-up). Methods: In this multicenter, nonrandomized 2-cohort study, pts with histologically confirmed laBCC (deemed inoperable or for whom surgery would be significantly disfiguring) or mBCC with RECIST-measurable disease, received 150 mg oral vismodegib daily. Introduction: The identification of responding patients early during treatment would greatly improve the efficacy of novel and costly immunotherapies. Bioassays which accurately link preceding immune responses to clinical outcome are therefore needed. The mainstay of immunotherapy is to induce, enhance or sustain TAA-specific effector T cell immunity. Consequently, evaluation of the migratory-, antigen recognition-, as well as the effector function of tumor-specific cellular responses is critical. Methods: A large cohort of metastatic melanoma patients (n = 91) enrolled in dendritic cell (DC)-based vaccination protocols was retrospectively analyzed for overall survival (OS) in relation to skin-test infiltrating lymphocyte (SKIL) cultures characteristics. Increasingly stringent criteria were defined identify long-term survivors.
Results: The presence of TAA-specific CD8 + T cells (criterion I: detection by tetrameric MHC-peptide complexes) in SKIL cultures associated with improved OS; 14.1 versus 10.9 months, p = 0.055. Further analyses showed that the presence of multiple specificities was highly predictive for long-term survival. Tumor recognition by TAA-specific CD8+ T cells on peptide level (detected by specific production of Thelper 1 (Th1) cytokines (criterion II; e.g. IFNg and/or IL-2) or cytotoxicity and no Thelper 2 (Th2) cytokines) was strongly associated with improved OS; 14.2 versus 10.2 months, p = 0.003. Recognition of naturally processed antigen by specific production of Th1 cytokines or cytotoxicity and no Th2 cytokines ((criterion III), maximized the accuracy of the test; 24.1 versus 9.9 months, p = 0.001. Conclusion: Our results demonstrate that analyzing SKIL cultures is a solid bioassay to predict overall survival in metastatic melanoma patients. This bioassay is simple, feasible and integrates multiple aspects of cellular functions needed for effective immune responses. Disclosure: All authors have declared no conflicts of interest. ); Arm B: RAM (10 mg/kg). Rx was every (q) 3 weeks (wk); tumor assessments were q6 wk. The primary endpoint was progression-free survival (PFS); other endpoints were safety, response, overall survival (OS). Results: 106 pts were randomized; 102 received study Rx. Arm A (n = 52) median (medn) age was 63, 71% male, 37% had elevated LDH, 23% stage M1c. Arm B (n = 50) medn age was 62, 76% male, 38% had elevated LDH, 36% stage M1c. Medn PFS was 2.6 months (m) Arm A and 1.7m Arm B; 6m PFS rates were 31% and 18%; 12m PFS rates were 24% and 16% on Arms A and B, respectively. (Prieto et al, CCR, 2012) . Evaluation of the long-term survival benefit of IPI for MM pts from 3 additional completed phase II studies continues and we now report 5-yr survival data. Methods: Trials included: (1) CA184-008, a single-arm study of IPI at 10 mg/kg in previously treated pts; (2) CA184-022, a dose-ranging study of IPI at 0.3, 3, or 10 mg/kg in previously treated pts with crossover from lower doses to 10 mg/kg allowed upon disease progression; and (3) CA184-007, a study of IPI at 10 mg/kg +/-prophylactic budesonide in treatment-naive and previously treated pts. IPI was given q 3 wks x 4 (induction); eligible pts could receive reinduction or maintenance IPI q 12 wks from Week 24. The analysis reports OS with updated last known alive date or death based on data collected through March 2012. Safety data for these trials have been previously published. Results: Survival rates at 5 yrs ranged from 12-28% in pretreated pts and 38-50% in treatment-naive pts. The table summarizes median OS, previously reported yearly survival rates, and current 5-yr survival rates. (Hodi et al., NEJM 2010; Robert et al. NEJM 2011; Prieto et al., CCR 2012) . We have previously reported a significant clinical efficacy of IPI in 27 heavily pre-treated MM pts enrolled within the 10 mgs expanded access program (EAP) available at the University Hospital of Siena; one and 2-years survival were 34.8% and 23.5%, respectively (Di Giacomo, et al. CII, 2010) . In spite of its clinical efficacy, no definitive predictive markers of response have been identified yet. We report here the survival follow-up of this cohort of MM pts and preliminary data on immunological correlates. Methods: Twenty-seven pts with stage III (2) or IV (25) MM, progressing to a median of 3 (1-5) systemic therapies, were treated according to the EAP with IPI at 10 mg/Kg i.v. given at weeks (wks) 1, 4, 7, 10 during the induction phase, and every 12 wks from W24 in the maintenance phase. Peripheral blood mononuclear cells were collected from 17 pts at baseline, W7, W12 and W24 and analyzed by flow cytometry for ICOS expression on both CD4 and CD8+ T cells. The ratio between absolute blood neutrophils (N) and lymphocytes (L) count was determined at baseline, W4, W7 and W10 for 27, 27, 24 and 23 pts, respectively. Results: With a median follow-up of 9.6 months the median OS was 9.6 months (95% CI: 4.2-16.1; range: 3.1-51.2; three and 4-years survival rates were 20.9%, with 5 long-term survivors (>4 yrs). A significant ( p < 0.05) increase in the percentage and absolute number of CD4 + ICOS+ and CD8 + ICOS+ circulating T cells was observed from W7 on. Compared to baseline, pts with a fold increase in CD4 + ICOS+ and CD8 + ICOS+ T cells higher than 4 at W7 and W12 experienced a clinical benefit (SD, PR and CR). Pts with a N/L ratio lower than median at W7 and W10 had a significantly better survival. . The age of onset was significantly lower and the number of primary melanomas higher in patients with mutations. CDKN2A mutations were significantly more frequent in patients with familial history of melanoma (5/9; 56%) compared with patients without (1/54; 2%) (P < 0.001), and in patients with more than two melanomas (3/9; 33%) compared with patients with only two melanomas (3/54; 6%) (P = 0.012). The debated A148T polymorphism was found at low level (2/54; 4%) in our series. Regarding genetic alterations at somatic level, BRAF mutations were identified in 36/100 (36%) primary melanoma tissues, whereas amplification of cKIT and CyclinD1 genes was observed in 2/88 (2%) and 10/88 (11%) analyzed tissue samples, respectively. Considering all types of genetic events, paired samples presented a poorly consistent distribution of somatic alterations in same patients (52% consistency). Conclusions: Coexistence of MPM and familial recurrence of melanoma as well as the presence of more than two melanomas seem to be strong indications to address patients to CDKN2A mutational screening. The low consistency in genetic patterns of primary tumors from the same patients provide additional evidence that pathogenetic mechanisms of melanomagenesis are heterogeneous and molecularly different cell types may be generated in multiple primary melanoma. Disclosure: All authors have declared no conflicts of interest. (1.05-3.31) , respectively]. Finally compared with high SES, the risk of melanoma-related death, adjusted for age and sex, was 7 times higher (hazard ratio, 7.44; 95% CI, 3.27-16.93) in patients with low SES living alone. Conclusion: Our data for the first time demonstrates that BT and survival decreased over time but not for low SES patients. These pts should be considered the optimal target for future prevention campaign Table 1 Background: Recently we found that SNPs alter the oropharynx carcinoma risk in tumor suppressor MCC c.*5077A > G, PTCH1 g.79755C > T, and PTCH1 g.79456C > T. This study was conducted using high-resolution large-scale DNA microarray genotyping (5.0 SNP array, Affymetrix ®), and the quantities and functions of the proteins encoded by distinct alleles of the polymorphisms are being examined by our research group. Objective: We aimed to verify whether the different genotypes of polymorphisms in MCC c.*5077A > G, PTCH1 g.79755C > T, and PTCH1 g.79456C > T alter the CM susceptibility. Background: P53 (guardian of the genome), MDM2 (p53 inhibitor), BCL2 (anti-apoptotic) and BAX (proapoptotic) genes remove cells damaged by ultraviolet (UV) rays of sunlight and, therefore, are related to the origin of cutaneous melanoma (CM). All these genes are polymorphic in humans. The Arg wild allele of the P53 Arg72Pro polymorphism is more efficient than the variant Pro allele at inducing apoptosis. The variant G and A alleles of MDM2 T309G and the BCL2 C (-948) A polymorphisms, and the variant A allele of the BAX G(-248)A polymorphism are related to higher and lower expressions of the encoded proteins, respectively, than their wild T, C and G alleles. This study aimed to clarify the roles of the above-mentioned genetic polymorphisms in the risk and clinical manifestation of the tumor. Material and methods: In this case-control study, genomic DNA from peripheral blood of 150 consecutive CM patients (75 males and 75 females, 138 Caucasians and 12 non-Caucasians aged 20-89 years) and 150 healthy subjects, matched by age, gender and race, was analyzed by polymerase chain reaction followed by enzymatic digestion. Results: The frequencies of the P53 ArgArg and the BCL2 AA genotypes were higher in patients than in controls (58.7% versus 44.7%, P= 0.01) and (28.0% versus 15.3%, P= 0.004), respectively. Carriers of these genotypes had a 1.86 and 2.87-fold increased risk for CM than those with the remaining genotypes, respectively. Excesses of the P53 ArgArg plus BCL2 AA and P53 ArgArg plus BAX AA were seen in patients when compared to controls (36.1% versus 16.9%, P= 0.002) and (29.5% versus 15.3%, P= 0.008). Carriers of these genotypes had a 3.43 and 2.71-fold increased risk for CM than others, respectively. Conclusions: The data suggest that P53 Arg72Pro, BCL2 C(-248)A and BAX G (-248)A polymorphisms, alone or combined, alter the risk for CM in our region. We believe that carriers of specific genotypes of the above-mentioned genes should receive additional recommendation to avoid exposition to sunlight, in addition to frequently being evaluated by a dermatologist for early disease diagnosis. Medical Oncology, Clinica Universitaria de Navarra, Pamplona, SPAIN, high response rates and prolonged progression free survival. These results emphasise the importance of molecular information, even in those cases in which the diagnosis is made on small samples obtained through minimally invasive approaches. Cytology is an accurate and cost-effective tool for the diagnosis of MM and cytological smears are occasionally the only samples available from these patients. Methods: We have studied BRAF and c-KIT mutations in 62 cytological samples from MM patients. Preliminary results of 56 cases (32 men (58%) and 23 women (42%); median age 52 years) are included in this abstract. Diagnosis was made on fine needle aspiration in 41 cases, imprints in 10, direct eye touch in 1, a smear from cellular culture in 1, and pleural and peritoneal fluid in 3. To assure tissue quality, DNA was extracted directly from Papanicolau stained smears on which cytological diagnosis was made. BRAF and c-KIT mutations were analysed by PCR and direct sequencing using an ABI PRISM TM 310XL. Results: BRAF mutations was found in 30 cases (53.5%): V600E mutation in 26 (86,7%) and V600K in 4 (13,3%). c-KIT mutations were studied in 18 cases. L576P mutation was present in 1 patient with liver metastasis from acral melanoma (5.56%). BRAF status did not correlated with primary melanoma histology, age at diagnosis, disease free survival, brain metastases rate and overall survival. Conclusions: The frequency of activating mutations in BRAF is 53.5% in this series. V600E is the most commonly observed mutations, but V600K appears in 13.3% of the cases. c-KIT mutations incidence is low (5.56%). Mutational analysis of BRAF and c-KIT using cytological samples from patients with metastatic melanoma is feasible and can be used to extend the benefits of targeted therapy to those patients from which biopsies are not available. Updated results will be presented. Background: Vemurafenib, a BRAF inhibitor, is associated with improved progression-free survival and overall survival in patients ( pts) with BRAF V600 -mutant metastatic melanoma (mM). Here we present findings from a safety study of vemurafenib in pts with unresectable Stage IIIC/IV BRAF V600 -positive mM. Methods: Pts with untreated or previously treated Stage IIIC/IV BRAF V600 mutation-positive (cobas® 4800 BRAF V600 Mutation Test) melanoma were enrolled. Pts received continuous oral vemurafenib 960 mg bid. Primary study endpoint was safety; efficacy (RECIST V 1.1) was a secondary endpoint. Results: Of 5273 screened pts (Mar 2011 -Feb 2012 , 2353 (45%) were enrolled and 2096 received ≥1dose of vemurafenib. Median age was 54 (16-95 years), 56% were male. Median time since first mM diagnosis was 6.4 months. Most pts were Stage IV (84%); 47.1% M1c, 2% Stage IIIC (stage not reported for 14% of pts). At baseline, 87% of pts had ECOG PS 0/1, 11% ECOG PS ≥2; 24% had brain metastases and 37% had elevated LDH. Most pts had received prior systemic therapy (60%) including ipilimumab (10%), MEK and BRAF inhibitors (3%). At data cut-off (29 Feb 2012), median treatment duration was 3.1 months (<1-11.2 months). Of 2096 pts, 1792 (86%) have reported AEs, 76% were related to vemurafenib, 32% Grade 3 and 2.3% Grade 4. Most common Grade 3/4 AEs were rash (2.8%), arthralgia (2.5%), fatigue (1.3%) and cutaneous squamous cell carcinoma/keratoacanthoma (6.0%). Most common AEs (>10%) of any grade were arthralgia (30.7%), rash (25.6%), fatigue (19.6%), alopecia (15.6%), nausea (15%) and photosensitivity (11%), and were similar irrespective of brain metastases and ECOG PS. AEs caused treatment interruption in 492 (23.5%) pts. Of 774 pts (37%) who discontinued treatment, most withdrew due to progressive disease (71%) or death (14%) but 6% had AEs (most commonly general physical deterioration). Tumour assessments at Week 8 of treatment were available for 1356/2096 (65%) pts; 60% of pts achieved a CR or PR; 31% had SD. Conclusions: In a setting representative of routine clinical practice, vemurafenib is well tolerated and both safety profile and activity resemble the Phase I-III data, although this analysis is limited by the study duration. Radiology, MRI Bethanien, Zurich, SWITZERLAND Background: The BRAF inhibitor vemurafenib has shown high response rates and improved progression-free and overall survival in mM harbouring V600-mutated BRAF. BMs are often observed with mM and indicate a poor prognosis. The aim of this preliminary investigation is to determine the feasibility of vemurafenib therapy in mM with BM. Methods: 24 evaluable pts with BRAF V600 mutation positive (cobas® 4800 BRAF V600 Mutation Test) mM and BMs, requiring corticosteroids for symptom control, were enrolled (Nov 2010-Nov 2011). Pts received twice-daily vemurafenib 960 mg. Primary endpoint is safety; secondary endpoint is best overall response rate (RECIST v1.1). Results: All pts were white, median age 47 (24-70) years. Median baseline number of BMs was 3.5 (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) . Median time since BM diagnosis was 3.2 (0-64) months. Other lesion sites included skin, lung, liver, bone, lymph nodes, colon/large intestine, stomach, breast and adrenal. All pts had prior treatment for BM: radiotherapy 83% (58% whole brain, 25% precision), 2 pts had surgery and 83% of pts had systemic therapy. As of clinical data cut-off (15 Dec 2011), median treatment duration was 117 (3-304) days. 9 pts are ongoing; 15 (63%) discontinued treatment because of progression of disease (PD), 8 of whom died because of PD. 22 pts (92%) reported ≥1 adverse event (AE), which were mainly mild or moderate. Most common AEs were arthralgia (33%), photosensitivity (21%) and seizures (20%, pre-existing). 3 pts reported 1 of each of the following grade 3 AEs: epilepsy, cutaneous squamous cell carcinoma (cuSCC), increased amylase, elevated γ-glutamyltransferase and ileus with perforation. Overall, cuSCC occurred in 3 pts (12.5%), skin papilloma in 3 pts (12.5%) and keratoacanthoma in 1 pt (4.2%). 7/24 pts (29%) had a confirmed partial response: 9 pts (38%) had stable disease, 3 (12%) PD and 5 (21%) were not evaluable for response. Median duration of response was 3.8 (0.8-4.7) months. Conclusions: Vemurafenib therapy is feasible in advanced melanoma patients with symptomatic BM. Interpretation of efficacy is currently limited because of a short follow-up time, but there are strong indications of vemurafenib activity in BM. Disclosure: R. Dummer: Research funding: Astra Zeneca, Novartis, Cephalon, MSD, Transgene, BMS, Roche, GlaxoSmithKline, Bayer. Ad-board: Astra Zeneca, Novartis, Cephalon, MSD, Transgene, Genta, Bayer, Roche, BMS, GSK, Spirig. L. Mitchell: Full-time employee of F. Hoffmann-la-Roche. L. Veronese: Full time employee at F. Hoffmann-la-Roche. All other authors have declared no conflicts of interest. 12 and repeated every 4 weeks until disease progression or unacceptable toxicity occurred. The primary endpoint was progression-free survival (PFS) rate at 6 months. Responses were evaluated using immune-related response criteria.
Results: Sixty-four pts were enrolled and received at least one dose of study drug. All pts were included in the analysis. With a median follow-up of 51 weeks, the PFS rate at 6 months was 45%, exceeding the proposed rate of 30%, and the median PFS was 22 weeks. There were 10 (15.6%) confirmed complete responses and 10 (15.6%) confirmed partial responses. To date, median overall survival has not been reached. Among many variables including age, gender, ECOG PS, and stage, there was a statistically significant difference in PFS in the group of patients with bone metastasis and those without bone metastasis. Conclusion: At a median follow-up of 51 weeks, the overall response rate in this study is 31%. Ipi at 10 mg/kg in combination with Tem given in an induction followed by maintenance fashion is safe, well-tolerated, and efficacious in MM. The primary endpoint of 6-month PFS has been reached and exceeded. Melanoma-sarcoma Division, Memorial Sloan-Kettering Cancer Center, New York, NY, UNITED STATES OF AMERICA Background: Data from clinical trials suggest a long-term survival effect (beyond 4 yrs) of IPI therapy in some pts with MM. An analysis of 177 pts from 3 phase I/II IPI studies conducted at NCI demonstrated 5-yr survival rates of 13-25% (Prieto, et al., CCR 2012) . In other phase II trials, IPI monotherapy was associated with long-term survival of 4+ yrs in some pts with MM (Wolchok, et al., 2011 PIM) . IPI in combination with DTIC in previously untreated MM patients significantly improved OS in phase III study CA184-024 (Robert, et al, NEJM 2011) . Safety data from study 024 has been previously published. Here we report 4-yr survival data from study 024, the longest IPI survival follow-up from a phase III study. Methods: Pts with treatment-naive MM were randomized to receive either IPI (10 mg/kg) + DTIC (850 mg/m 2 ) or placebo + DTIC (850 mg/m 2 ) given at Wks 1, 4, 7, 10 followed by DTIC q 3 wks through Wk 22. Pts with stable disease or better then received IPI or placebo q 12 wks as maintenance. This analysis reports OS with updated last known alive date or death date based on data collected through April 2012. Results: The table summarizes median OS, previously reported survival rates at 1, 2, and 3 years, and current analyses for 4-year survival rates by treatment group.
Conclusions: The 4-year survival rates observed in an extended follow-up of a completed phase III trial suggests that IPI 10 mg/kg in combination with DTIC continues to demonstrate a survival benefit compared to the control arm. The continued survival of some patients at 4 yrs suggests that prolonged survival may indeed be obtained in some pts with treatment-naive MM. This observation of long-term survival benefit in a phase III RCT is consistent with observations from phase I/II studies of IPI in patients with advanced melanoma. Background: Treatment protocol CA184-045, a component of the EAP, provides a large safety database for IPI. Study 045 included pts with disease characteristics typically excluded from registrational clinical trials such as ECOG PS of 2, asymptomatic brain metastases (BM) and primary ocular (OM) and mucosal (MM) melanoma. We now report safety data by subgroups for pts treated in the US at 3 mg/kg from March 2010 through July 2011. Methods: Eligible pts had unresectable Stage III or IV melanoma that progressed on at least 1 systemic therapy and had no alternate treatment options. Treatment algorithms were used for identification and management of immune-related adverse events (AEs). During induction, pts received 3 mg/kg IPI iv q 3 wks up to 4 doses. All AEs and on-study deaths were collected. This analysis includes events through 70 days post last induction dose. Purpose: Mucosal melanoma is an extremely rare and aggressive malignancy associated with a poor prognosis. Because of its rarity and the challenges associated with each anatomical location, mucosal melanoma often remains undetected until it is at an advanced stage, when effective treatment options are limited. The EAP provided an opportunity to assess the activity and safety of ipilimumab in patients with mucosal melanoma outside of controlled clinical trials from the EAP in Italy. Methods: Ipilimumab was available upon physician request for patients aged ≥16 years with stage III (unresectable) or stage IV skin, ocular or mucosal melanoma, who had failed or did not tolerate previous treatments and for whom no therapeutic option was available. Patients were treated with ipilimumab 3 mg/kg every 3 weeks for 4 doses. Tumour assessments were conducted at baseline and after completion of induction therapy using immune-related response criteria. Patients were monitored for adverse events (AEs), including immune-related AEs, within 3 to 4 days of each scheduled visit using Common Terminology Criteria for Adverse Events v.3.0. Results: Of 848 Italian patients participating in the EAP, 70 (8.2%) had mucosal melanoma. Of these, data are available for 50 patients. With a median follow-up of 2.5 months, the disease control rate among 39 evaluable patients was 23.1%, including one patient with a complete response, two patients with a partial response and six with stable disease. As of April 2012, median progression-free survival and overall survival among patients with mucosal melanoma were 3.9 months and 6.2 months, respectively. In total, 40.0% patients reported an AE of any grade, most of which were drug-related (32.0%). Grade 3/4 AEs were reported by 18.0% patients and considered drug-related in 12.0%. AEs were generally manageable and most resolved with treatment as per protocol-specific guidelines. Conclusions: Results from the EAP suggest that ipilimumab is active in some patients with mucosal melanoma and warrants further investigation in prospective clinical trials. Methods: Ipilimumab was available upon physician request for patients aged ≥16 years with unresectable stage III /IV melanoma, including those with asymptomatic brain metastases, who had either failed systemic therapy or were intolerant to ≥1 systemic treatment. Induction therapy with ipilimumab was 3 mg/kg every 3 weeks for 4 doses. Tumour assessments were conducted at baseline and after completion of induction therapy using immune-related response criteria. Patients were monitored for adverse events (AEs), including immune-related AEs, within 3 to 4 days of each ipilimumab dose using Common Terminology Criteria for Adverse Events v.3.0. Results: Of 848 patients with advanced melanoma participating in the EAP in Italy, 144 (17%) had asymptomatic brain metastasis. Of these, data are available for 84 patients. With a median follow-up of 3 months, the disease control rate among 74 evaluable patients was 16.2%, comprising four patients with a partial response and eight with stable disease. As of April 2012, median progression-free survival and overall survival among patients with brain metastases were 2.5 months and 3.8 months, respectively. In total, 50.0% patients reported an AE of any grade, most of which were drug-related (40.5%). Grade 3/4 AEs were reported by 28.5% patients and considered drug-related in 15.5%. The most common grade 3/4 drug-related adverse events were diarrhoea (n = 3; 3.6%) and liver dysfunction (n = 3; 3.6%). AEs were generally reversible with treatment as per protocol-specific guidelines. Unit of Medical Oncology and Innovative Therapy, Istituto Nazionale Tumori Fondazione G. Pascale, Napoli, ITALY Purpose: Ocular melanoma is a rare malignancy with an incidence of 5.3-10.9 cases per million per year (Papastefanou and Cohen; J Skin Cancer 2011). Currently, the treatment of metastatic ocular melanoma is limited by the lack of an effective systemic therapy. The EAP provided an opportunity to assess the activity and safety of ipilimumab in patients with ocular melanoma outside of a controlled clinical trial in patients from the EAP in Italy. Methods: Ipilimumab was available upon physician request for patients aged ≥16 years with stage III (unresectable) or stage IV skin, ocular or mucosal melanoma, who had failed or did not tolerate previous treatments and for whom no therapeutic option was available. Patients were treated with ipilimumab 3 mg/kg every 3 weeks for 4 doses. Tumour assessments were conducted at baseline and after completion of induction therapy using immune-related response criteria. Patients were monitored for adverse events (AEs), including immune-related AEs, within 3 to 4 days of each scheduled visit using Common Terminology Criteria for Adverse Events v.3.0. Results: Of 848 Italian patients participating in the EAP, 83 (9.8%) had ocular melanoma. Of these 83 patients, 55 have data available. With a median follow-up of 3 months, the disease control rate among 46 evaluable patients was 34.8%, including 3 patients with a partial response and 13 with stable disease. As of April 2012, median progression-free survival and overall survival among patients with ocular melanoma were 2.9 months and 5.9 months, respectively. In total, 63.6% patients reported an AE of any grade, most of which were drug-related (47.3%). Grade 3/4 AEs, which were reported by 20.0% patients, were only considered drug-related in 5.4%. AEs were generally manageable and most resolved with treatment as per protocol-specific guidelines. Methods: At the end of the Phase III trial (MDX010-20) 17% of patients receiving ipilimumab were alive compared to 4% of those receiving GP100: median follow up 28 months, maximum 55 months. Trial data were used to model survival beyond the trial period. GP100 has been shown to have no impact on survival (within MDX010-20 and a mixed treatment comparison). GP100 arm data were used to model survival of patients receiving BSC. Two groups were seen: Patients who experience therapy benefit and enter a stable period leading to a gradual plateau of the KM curve; Patients whose immune systems do not respond quickly and die causing an initial steep drop in the KM curve Standard modelling techniques did not fit the available data well and underestimated the durable response of immunotherapy. Around 18 months the mortality hazard was shown to change in the ipilimumab arm meaning that different methods were required to predict survival before and after this time. We estimated long-term survival as follows: · ≤18 Months Kaplan-Meier data was used, mimicking survival within the trial · >18 Months -5 years (representing the maximum data available from MDX-010-20) a standard parametric curve was fitted to the data · >5 years 15 year registry data from Balch et al (2001) for Stage IV melanoma and background mortality were used to estimate long-term survival. Results: Using the three-part approach reduced the mean absolute error (MAE) associated with the curve fits. Those selected having an MAE of 0.003 (0.004 for long-term survivors) on the ipilimumab arm, and 0.008 (0.012 for long-term survivors) on the BSC arm. This compares to a MAE at least 7 x higher (0.06) for standard parametric curves. For BSC patients, the model predicts mean survival of 1.2 years whereas those taking ipilimumab are expected to survive for a mean of 3.7 years. This is due to more patients remaining alive beyond 5-years, after which death from melanoma is less likely. Further progress is likely to come from novel targeted antiBRAF therapy, available for about 50% of pts, and from immunotherapeutic agents such as the mAb ipilimumab, at present available only in some countries. Preclinical and clinical experiences support the concept that continuous exposure to an alkilating agent can effectively deplete cells of the DNA repair enzyme O6-methylguanine DNA methyltransferare, the primary mechanism of tumor resistance to chemotherapeutic agents like nitrosurea analogs. Our study was finalized to verify this hypothesis using a sequential combination of low dose chemo-modulating TMZ and FM. Primary endpoints were safety and tumor response evaluation. Methods: 53 consecutive MM pts were enrolled in the study. The majority of them (80%) were enrolled before the targeted therapy. The main characteristics included: median age 56 years (21-79); ECOG PS 1 (0-2); number of disease sites: 1 in 30%, 2 in 27%, >2 in 43%; M status: M1a 9%, M1b 21%, M1c 70% with 5 pts having brain metastases. The following schedule was used: oral TMZ 100 mg/m2 d 1 and 2; FM iv 100 mg/m2 d 2, 4 h after TMZ. The regimen was repeated every 3 weeks for a maximum total of 9 cycles. Tumour assessments were conducted at baseline and then every 3 cycles. Results: 52 pts are evaluable for toxicity and 51 for clinical assessment (1 withdrew consent prior to starting treatment; 2 early). The median number of treatment cycles administered was 7 (range 2-9). There were 13 (25%) responses (1 CR and 9 PRs) with a median duration of 7 months, and 12 (23%) stable disease. Median progression-free survival was 6 months and median overall survival 11+ months (range 2-35+ months). Drug-related toxicities ≥ grade 3 included thrombocytopenia (10%), neutropenia (6%), anemia (2%), and hepatopathy (2%). Approximately 75% of pts were treated without dose reduction. Two patients (4%) discontinued therapy because of toxicities. Conclusions: sequential low dose TMZ and FM demonstrated a high activity in our patient population with an acceptable toxicity. This schedule could therefore represent a good alternative for patients not eligible for targeted therapy or in whom previous targeted therapies failed. The study of the correlation between MGMT level and clinical outcomes is ongoing. Disclosure: All authors have declared no conflicts of interest. F-FDG-PET/CT was negative for metabolic activity in 6 patients and positive in 28 patients. All 6 patients with negative 18 F-FDG-PET/CT were histologically confirmed. Metastatic disease treatments were: chemotherapy (27 patients), liver surgery (9 patients), liver stereotactic radiotherapy (2 patients), liver radiofrequency ablation (1 patient). Median OS was 18.8 months (CI 95% 7.2-30.4). Median OS was significantly higher ( p = 0.001) in patients with 18 F-FDG-PET-negative (median not reached) than in patients with 18 F-FDG-PET-positive (15.1 months, CI 95% 11.5-18.7). Assessed as a continuous variable, maximum SUV in the liver was correlated with OS ( p = 0.002, HR 1.1, CI 95% 1.03-1.2). Maximum SUV greater than 5 was related with poor prognosis ( p = 0.025). Major diameter of LM in 18 F-FDG-PET/CT was significantly correlated with OS ( p < 0.001). LM greater than 20 mm were related with poor prognosis ( p < 0.001). By multivariate analysis, major diameter of LM ( p < 0.001) and 18 F-FDG-PET/CT status ( p = 0.001) remained significant survival predictors.
Conclusion: Metabolically

18
F-FDG-PET-negative liver metastases correlated with better OS in patients with metastatic uveal melanoma. Disclosure: All authors have declared no conflicts of interest.
Intralesional rose bengal (PV-10) is being investigated for treatment of solid tumors, where it may elicit selective chemoablation of injected lesions and a tumor-specific, immune-mediated bystander response in untreated bystander lesions. In phase 1 testing in 20 subjects with AJCC Stage III-IV melanoma, single-dose treatment with PV-10 was well tolerated, producing a durable objective response (OR) at 12-24 weeks in 40% of subjects (20% CR + 20% PR by modified RECIST) and locoregional disease control (CR + PR + SD) in 75% of subjects; 15% of subjects achieved an OR in bystander lesions, which strongly correlated with response of their injected lesions. Phase 2 testing in 80 subjects with Stage III-IV metastatic melanoma (median age 70.0 yrs, range 33-97) commenced at 7 centers in Australia and the USA in October 2007 with final clinical evaluation completed in May 2010 (Clinical Trials ID NCT00521053). In this study, subjects could receive up to four courses of PV-10 to up to 20 cutaneous or subcutaneous lesions (median 2 courses, range 1-4). Preliminary study data was presented at SMR 2010 in Sydney, Australia, and showed that treatments were well tolerated, with adverse events predominantly mild to moderate, locoregional and transient, with no grade 4 or 5 AEs attributed to PV-10. Preliminary evaluation also showed robust response, with 24% of subjects achieving a CR, 25% PR and 22% SD of their target lesions. Additionally, 24% of 38 subjects with evaluable, untreated bystander lesions achieved CR in their bystander lesions, along with 13% PR and 18% SD. As observed in phase 1, response of bystander lesions strongly correlated with response of injected lesions. Final efficacy data will be presented, including response rate and time-to-event ( progression free survival and overall survival). These data demonstrate that the safety and efficacy profile of PV-10 compares favorably with available and emerging treatment options for this patient population, and serve as the basis for phase 3 testing of PV-10 in Stage III patients with recurrent, in-transit or satellite metastases. A randomized controlled trial to assess PFS against standard care is expected to commence in the second half of 2012 at centers in Australia, the USA and the EU. Introduction: We performed a vaccine trial in metastatic melanoma patients with a stable disease course. Aim: Primary end point was 6-month progression-free survival; secondary end points included overall survival, progression free survival, immunological parameters. Patients and methods: Inclusion criteria were morphologically proven metastatic melanoma, ECOG status 0-2, LDH level <= 1,5N, RECIST-evaluable lesions. Any adjuvant treatment and one line of the metastatic melanoma treatment were allowed. Patients with brain metastasis were excluded. All patients scheduled to receive 2 cycles of the polychemotherapy with cisplatin 20 mg/m 2 day 1-4; vinblastine 2 mg/ m 2 day 1-4 and DTIC 800 mg/m 2 day 1, cycle 28 days. On day 14 of cycle 2 assessment was predefined. Patients who progressed after two cycles of the chemo were excluded from the study. All other patients were randomized to 3-d cycle of the chemo followed by one vaccination cycle or three cycles of the chemo. Vaccination schedule consisted of 5 subcutaneous injections of DC vaccine (2,000,000 cells) with 14 days intervals. Assessments were performed every 5 vaccine injections (10 wks) in DC-group and every 2 cycles (10 wks) in chemo group. Results: From March 2010 to April 2012 101 patients were included in the study. After 2 cycles of chemo in 34 patients disease progression was detected. Of the 67 patients effects were not assessed in 3 patients. 31 patients were randomized to the DC-group and 33 to the chemo group. 6 pts were switched to chemo immediately after randomization and did not receive the vaccine. The 6-month PFS in per protocol population was 52.6% in the DC group and 15% in the chemo (RR = 0.56; 95% CI 0.34 to 0.97, p = 0.03). Median PFS was 7.38 mo in the DC group and 4.9 mo in the chemo group (95% CI 6.3 to 8.5 and 3.3 to 6.4, respectively, not significant). Median OS was 13.4 mo in the chemo group and was not reached in the DC group. Immunological testing suggested that population CD4 + CD25hiCD127+ (Tregs) did not predict therapy success and did not significantly change during the treatment. Conclusion: Dendritic cell vaccine immunotherapy may be a less toxic option for maintenance therapy in patients with metastatic melanoma with stable disease course. Additional trials are needed to compare such a vaccine with best supportive care or placebo. Disclosure: All authors have declared no conflicts of interest. Uveal melanoma (UM) is the most frequent eye cancer (annual incidence 0.5-0.7:100000), 40% to 60% of patients develop metastases; of them, up to 95% experience liver involvement. Metastatic disease carries a poor prognosis and no standard therapy is established so far. We retrospectively reviewed the medical records of 127 consecutive patients (M/F:61/65) with metastatic UM treated at our institution from September 1990 to February 2012. We collected: gender, age, TNM stage, data and site of primary UM and metastases; LDH, alkaline phosphatase, gGT, transaminases; treatments and outcome. Mean age at diagnosis of primary UM was 56.4 years (median 59.8, 95% CI 53.7-59.1 years). Mean age at diagnosis of first metastasis was 58.8 years (median 62.4, 95% CI 56.1-61.5 years), with a mean disease-free interval (DFI) of 3.6 years (median 1.9, 95% CI 1.9-5.3 years). Ninetynine (78%) patients had liver metastases (LM), 28 (22%) had local or nodal involvement, 9 (7.1%) had lung metastases and 13 (10.2%) had other visceral metastases (CNS, kidney, spleen, adrenal gland, bone), 30 (23.6%) patients had multiple sites of disease. Lung metastases were more frequent in females (OR 9.17, p = 0.037) . LDH and gGT levels at the first metastasis onset, were inversely correlated with survival ( p < 0.05). Survival was significantly poorer in LM bearers (13% versus 55% 1 year survival, p < 0.01). Longer DFI was a prognostic factor for not hepatic recurrence and better prognosis (logistic regression, OR 0.88, p < 0.05) . Age at diagnosis correlated with age at recurrence and with longer DFI ( p < 0.05). Considering all treatments, almost always combining locoregional and systemic therapy with fotemustine, [hepatic intra-arterial fotemustine, radiofrequency, alcoholization, surgery, intra-arterial hepatic chemoembolization with camptothecin charged microbeads (TACE)], only TACE was associated with an improved prognosis (OR 0.17, p < 0.01) and with a longer survival after metastasis diagnosis ( p= 0.02). Conclusions: TACE can be combined with systemic therapy and provides a clinical benefit in UM metastases, this encourages further prospective studies, also in combination with anti-angiogenic drugs and systemic therapies. Disclosure: All authors have declared no conflicts of interest. Unwanted systemic exposure is minimized by extracorporeal filtration of hepatic venous blood. Methods: A prospective randomized multicenter phase 3 study compared CS-PHP of melphalan with BAC in pts with proven unresectable hepatic metastases from ocular or cutaneous melanoma. A survival update was performed on 31 March 2011. CS-PHP melphalan 3.0 mg/kg ideal body weight was infused into the hepatic artery over 30 min with concurrent extracorporeal filtration for 60 min. Up to 6 treatments were given every 4-8 wks. In the BAC group, crossover to CS-PHP melphalan was permitted after hepatic disease progression. The primary endpoint was investigator-assessed hepatic progression-free survival (hPFS). An exploratory post-hoc analysis of pts who crossed from BAC to CS-PHP vs. BAC-only pts was also performed. Results: 93 pts were randomized to CS-PHP (n = 44) or BAC (n = 49). After hepatic disease progression, 28 pts crossed over to CS-PHP. Results are shown in the Table. The most common grade 3/4 toxicities in CS-PHP pts (n = 40) were hematological peri-procedural thrombocytopenia (73%) and anemia (55%) and post-procedural (beyond day 4 post-treatment) neutropenia (93%) or thrombocytopenia (83%). The safety profile in crossover pts was similar to that in pts randomized to CS-PHP melphalan.
1141P PERCUTANEOUS HEPATIC PERFUSION (CHEMOSAT® OR CS-PHP) OF MELPHALAN VS. BEST ALTERNATIVE CARE (BAC) IN PATIENTS (PTS) WITH HEPATIC METASTASES
Conclusions: CS-PHP melphalan significantly prolonged hPFS compared with BAC in pts with liver-dominant metastatic melanoma, thereby meeting the primary study objective. Efficacy was similar after hepatic disease progression in BAC-CS-PHP crossover pts as in those randomized initially to CS-PHP. Pathology and Clinical Laboratory Division, National Cancer Center Hospital, Tokyo, JAPAN Background: HER2-targeted therapies have been introduced to treat breast and stomach cancers that show HER2 protein overexpression and/or HER2 gene amplification. However, the HER2 status of primary tumors and their corresponding metastatic sites is shown to be heterogeneous in less than 20% of cases. In extramammary Paget's disease (EMPD), HER2 protein overexpression and gene amplification has been shown to occur in 5-80% of cases; however, knowledge regarding the concordance of HER2 status in primary and metastatic sites of EMPD is limited. The aim of this study was to clarify the concordance rate of HER2 status in the primary tumors and metastatic sites of EMPD. Methods: Twenty-six tissue blocks of primary tumors and corresponding lymph node metastases were subjected to an immunohistochemistry (IHC) analysis. The IHC scores were classified into four groups (0 to 3+) according to the American Society of Clinical Oncology/College of American Pathologists Guidelines (2007) . When the primary tumors and lymph node metastases showed IHC scores of either 2+ or 3 + , the presence of HER2 gene amplification was examined using fluorescence in situ hybridization (FISH) and dual-colored in situ hybridization (DISH). Results: mmunohistochemically, 27% (7/26) of the primary tumors and 38% (10/26) of the lymph node metastases showed IHC scores of either 2+ or 3+. When HER2 protein overexpression was classified as being either positive (2 + , 3+) or negative (0, 1+), the concordance rate of the HER2 status of the primary tumors and corresponding lymph node metastases was 85% (22/26). The presence of HER2 gene amplification was examined in six primary tumors and 10 metastatic sites. HER2 gene was amplified in a total of seven cases (27%): four cases in both the primary and metastatic sites, two cases in the metastatic sites only and one case in the primary site only. Conclusion: Good concordance of HER2 protein overexpression and gene amplification status was seen in the primary tumors and corresponding lymph node metastases of patients with EMPD. Furthermore, the HER2 gene was found to be always amplified in cases with an IHC score of 3+ and in two cases with an IHC score of 2+ in the lymph node metastases, which is suitable to be targeted for therapy. Disclosure: All authors have declared no conflicts of interest. Background: Health-related quality of life (HRQL) is a fundamental part of health technology assessment. Utility values are vital because they can be used as preference weights and allow the calculation of HRQL benefits. The objective of this study was to compare utilities calculated for patients with advanced melanoma in the Phase III clinical trial for ipilimumab (MDX010-20) using a generic and a condition-specific preference-based measure to utilities produced by vignettes for advanced melanoma. A secondary objective was to determine how different analyses might be used most appropriately within cost-effectiveness modelling. Methods: The trial utilities were generated using the condition-specific EORTC-8D (1,190 observations) and generic SF-6D (1,157 observations) preference-based measures. Progression-status and time-to-death analyses were conducted on the patient-level data and the predictive abilities were compared. Patient-level results were compared to the utilities derived for progression status using vignettes valued by the general population. Results: On disease progression, vignette-generated utilities showed a greater decrease (0.77 to 0.59) than either the generic SF-6D (0.64 to 0.619) or condition-specific EORTC-8D (0.801 to 0.763). SF-6D and EORTC-8D showed a large decrease in utility in the 180 days prior to death (from 0.826 to 0.628 and from 0.655 to 0.505, respectively). Compared to progression status, time to death showed a lower Root Mean Squared Error and higher R2 when used to predict patient utility. Background: Treatment of metastatic squamous cell cancer of the skin (SCCS) is challenging. Only few therapeutic options including cisplatin-based combinations are currently available. In a recently published phase II trial, cetuximab, a monoclonal antibody against the epidermal growth factor receptor (EGRF), has demonstrated a promising clinical activity with an overall 69% disease control rate (DCR) and 28% response rate (RR) in patients with unresectable SCCS. Whether this treatment is also effective in metastatic SCCS is unclear. Purpose: To summarize the efficacy of cetuximab at any line in a series of patients with metastatic SCCS. Patients and methods: We performed a retrospective analysis of six patients from four centres in Switzerland. We collected standard baseline data by reviewing the patients' records. Endpoints were DCR at 4-8 weeks, 12-14 weeks and 20-36 weeks of treatment. In addition, we evaluated the treatment-related toxicity. Results: The median age of the patients was 67 years. A total of 10 cycles in median were applied (range 1-21). The DCR was 67% (4 of 6 patients) at 4-8 weeks, 50% (3 of 6 patients) at 12-14 weeks, and 33% (2 of 6 patients) at 20-26 weeks (Table 1) . One patient showed a complete response (CR) after 4 weeks of treatment and is still in remission since then. Death due to sepsis occurred in one patient. 83% (5 of 6 patients) developed Grade I-III acne-like rash around week 3 of treatment. All patients who had their disease controlled at 4-8 weeks showed an acne-like rash (4 of 6 patients), 1 patient had a rash without disease control. Conclusions: Cetuximab treatment in patients with metastatic SCCS achieved an overall DCR of 57% at 4-8 weeks of treatment. 1 of 6 patients had a CR. These data suggest that cetuximab may be effective in this setting.
Response and disease control rates. The test is based on mutant-enrichted PCR in the presence of a BRAF wild-type suppressor, followed by hybridization of PCR products to teststrips presenting a parallel array of allele-specific oligonucleotide probes. Bound sequences are visualized using streptavidin-alkaline phosphatase conjungate and colour substrates. The hybridization and detection steps can be carried out fully automated using commercially available instrumentation. Results: Plasmid clones served as reference DNA templates to control for specificity. StripAssay performance was evaluated on genomic DNA obtained from cultured cell lines and formalin-fixed paraffine-embedded (FFPE) tissue. Using normal DNA spiked with serial dilutions of DNA from the BRAF-mutant tumor cell lines HT29 or IGR-1, the mutations c.1799T > A (V600E) and c.1798_1799GT > AA (V600K) were shown to be detectable at a level of 1%. Conclusions: The simultaneous detection of nine different mutations with high sensitivity will make the StripAssay a very useful tool for the assessment of the BRAF mutation status of cancer patients. Disclosure: All authors have declared no conflicts of interest. Surgical Oncology, National Cancer Institute, Naples, ITALY Backgroud: Electrochemotherapy (ECT) has shown to be effective as local treatment of disseminated superficial melanoma, but there is a lack of evidence of its potential systemic effect. Potential immunologic changes due to ECT could have an impact on metastatic lesions but this hasn't been demonstrated yet. Combining ECT with new drugs, like ipilimumab (ipi), could be a new therapeutic strategy. T-regulatory cells (T-Reg) are immunosuppressive lymphocytes whose role during ipi therapy has still to be clarified. Our previous experience showed a reduction of T-reg cells in patients responder to ipi. Patients and methods: 20 patients with advanced melanoma (8 at stage IIIc and 12 IV M1c) underwent ECT with bleomycine. 5 patients were treated with ECT and no further therapies, while 15 pts were treated with ECT first and then, after progression, with ipi at 3 mg/kg for 4 cycles. We collected PBMC of these patients. Blood draw was performed at ECT day 0-1-15-30 and during follow-up, while during ipi therapy, at each cycle (week 4-7-10) and at every tumor evaluation (every 12 weeks).
Results: 5/20 (25%) patients, all at stage IIIc, had performed only ECT and showed a good local response (2 CR and 3 PR). No variation of T-Reg was detected after ECT treatment with median value of 0.40 % (range 0.40-2.6 %). 15/20 (75%) patients had a low local response and developed visceral progression after ECT without significant reduction of T-Reg levels. The median T-reg value was of 0.7 (range 0.50-2.6%) During ipi treatment, we found a decrease of T-Reg of 0.10% per cycle. This result was consistent with our previous evidence in patients treated with ipi in Italian EAP. Moreover, 3/15 patients (20%) showed local CR and 2 of them also systemic PR lasting at 12.1 months of follow-up, with a median T-Reg value of 0.10%. 8/15 (53%) had both local and systemic SD with a median TTP of 7.9 months and a median T-Reg of 0.30%. 4/15 (27%) developed a local and distant progression and we found a small decrease with median T-Reg of 1.8%. Conclusion: ECT followed by ipi in patients with metastatic melanoma, may be more effective than ECT and ipi alone. This combination may represent a new option. Anyway, further studies are necessary to verify these data. Disclosure: All authors have declared no conflicts of interest. Background: There is limited data on salvage chemotherapy for metastatic, non-cutaneous melanoma after failure to dacarbazine-based chemotherapy. Given the high incidence of non-cutaneous melanoma in Korea, we focused on the treatment outcome of paclitaxel/carboplatin as salvage chemotherapy in noncutaneous metastatic melanoma. Patients and methods: We retrospectively analyzed patients with metastatic melanoma who underwent paclitaxel and carboplatin (PC) chemotherapy as salvage treatment at Samsung Medical Center (SMC) between February 2009 and February 2012. The treatment schedule is as follows: intravenous paclitaxel 175 mg/m 2 plus intravenous carboplatin at area under curve 5 (AUC 5) on day 1 of a 21-day interval. Overall response rate, overall and progression free survival were calculated. Results: Thirty two patients (median age: 54 years, range 24 -72 years) were treated with PC as salvage chemotherapy. All patients were pretreated and had previously received a median of 2 systemic therapies. With respect to primary site, 10 patients (31.3%) had cutaneous melanoma, 8 (25%) had acral melanoma, 10 (31.3%) had mucosal melanoma, 2 (6.3%) had ocular melanoma. Of 32 patients, 7 patients achieved partial response (PR) (21.9%) and 11 patients were stable disease (34.4%). Median progression free survival (PFS) was 2.53 months for all patients. PFS was 4.3 months for patients controlled disease ( partial response and stable disease) compared to 1.37 months for patients with progressive disease ( p = 0.0001). Median overall survival was 5.2 months without a significant difference between noncutaneous and cutaneous metastatic melanoma group ( p =0.75). Conclusion: PC chemotherapy seems to be a reasonable therapeutic option in heavily pretreated metastatic melanoma patients. Especially, this combination chemotherapy appears to have definite and clinically meaningful activity when used as salvage therapy in metastatic melanoma including non-cutaneous melanoma. Disclosure: All authors have declared no conflicts of interest.
